Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
30 Results for "
TTK
" in MedChemExpress (MCE) Product Catalog:
Products (30)
30 Results for "TTK" in MCE Product Catalog:
12
7
CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity .
7
7 Cited Publications
Synonyms: CFI-402257 hydrochloride
CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity .
1
Target:
Research Areas:
TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of neurogenesis and long-term memory [1].CSP-TTK21 can ameliorate Aβ-impaired long-term potentiation (LTP). CSP-TTK21 may enhance the transcription of genes that promote synaptic health and cognitive function . CSP-TTK21 is orally effective and leads to improvements in motor functions, histone acetylation dynamics in a spinal injury rat model .
Cat. No.: HY-168543
Target:
Research Areas:
PROTAC AURKA degrader 3 is a selective AURKA PROTAC degrader, with DC50 values of 2.05, 157.85 and 43.05 nM against AURKA, AURKB and TTK, respectively. PROTAC AURKA degrader 3 exhibits cytotoxicity against acute myeloid leukemia cells. PROTAC AURKA degrader 3 can be used for research related to acute myeloid leukemia .
PROTAC TTK degrader-1 is a PROTAC degrader targeting Threonine Tyrosine Kinase (TTK), with a DC50 of 5.8 nM in HCT-116 cells and 1.7 nM in COLO-205 cells. PROTAC TTK degrader-1 induces the formation of a ternary complex with TTK and the CRBN E3 ubiquitin ligase, triggering proteasome-mediated degradation. PROTAC TTK degrader-1 exhibits activity against colon cancer cells and shows anti-tumor activity in a colon cancer xenograft mouse model. It can be used in colon cancer-related research .
NTRC 0066-0 is a selective threonine tyrosine kinase (TTK) inhibitor (IC50=0.9 nM). NTRC 0066-0 can be used for the research of cancer .
Cat. No.: HY-171770
CAS No.: 3115765-45-9
Target:
Research Areas:
dAurAB5 is a potent Aurora-A/Aurora-B PROTAC degrader with DC50 values of 8.8 nM and 6.1 nM, respectively. dAurAB5 promotes proteasomal degradation of target proteins, induces ubiquitination of Aurora-A and Aurora-B kinases, and downregulates the protein levels of TTK and MYCN. dAurAB5 can be used in studies related to neuroblastoma [1].
Cat. No.: HY-168540
Research Areas:
PROTAC MPS1 degrader 1 is a selective monopolar spindle 1 (Mps1/TTK) PROTAC degrader, with DC50 values of 17.7, 108.67 and 570.25 nM against TTK, AURKA and AURKB, respectively. PROTAC MPS1 degrader 1 exhibits cytotoxicity against acute myeloid leukemia cells. PROTAC MPS1 degrader 1 can be used in research related to acute myeloid leukemia .
Cat. No.: HY-168542
Research Areas:
TTK ligand 2 is a monopolar spindle 1 (TTK) ligand that can be used in the synthesis of PROTACT (HY-168540) .
Cat. No.: HY-132884
CAS No.: 2820453-41-4
TTK inhibitor 3 is a potent and selective TTK (an essential spindle assembly checkpoint enzyme) inhibitor with an IC50 value of 3.0 nM.
Cat. No.: HY-164955
CAS No.: 1817791-70-0
Target:
Research Areas:
TTK/PLK1-IN-1 (Formula I) is the inhibitor for threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC50 of 7 nM and 72 nM. TTK/PLK1-IN-1 regulates spindle assembly checkpoint (SAC), and exhibits antitumor efficacy against TNBC .
Cat. No.: HY-168545
Research Areas:
SF-1 is an AURKA ligand that can be used for the synthesis of PROTACs, such as PROTAC MPS1 degrader 2 (HY-168543). SF-1 can act as a free inhibitor and has the ability to pull down AURKA, AURKB, and TTK with DC50 values of 273.5, 933.5, and 1274 nM respectively. SF-1 has an anti-proliferative effect on acute myeloid leukemia .
Cat. No.: HY-143905
CAS No.: 2953426-48-5
PROTAC TTK degrader-2 is a threonine tyrosine kinase (TTK) PROTAC degrader with a DC50 of 3.1 nM in COLO-205 cells. PROTAC TTK degrader-2 induces proteasome-mediated degradation of TTK. It inhibits the proliferation of colorectal cancer cells. In colorectal cancer xenograft mouse models, PROTAC TTK degrader-2 mediates target degradation and exerts anticancer activity. PROTAC TTK degrader-2 can be used in colorectal cancer-related research .
Cat. No.: HY-162156
CAS No.: 2964520-80-5
TTK inhibitor 4 (compound 16) is a potent inhibitor of threonine tyrosine kinase (TTK), with the IC50 value of 0.016 μM, that has anti-tumor activity .
Cat. No.: HY-123675
CAS No.: 1338793-07-9
CFI-400936 is a potent TTK inhibitor with an IC50 of 3.6 nM. CFI-400936 has antitumor activity .
Cat. No.: HY-RS15226
Target:
Research Areas:
TTK Human Pre-designed siRNA Set A contains three designed siRNAs for TTK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS16792
Target:
Research Areas:
Ttk Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ttk gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
